Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07800572
PHASE2

Anisodine Hydrobromide for Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy (HEAL-2)

Sponsor: Capital Medical University

View on ClinicalTrials.gov

Summary

This phase 2, multicenter, randomized, double-blind, placebo-controlled trial will evaluate the efficacy and safety of anisodine hydrobromide in patients with acute ischemic stroke undergoing endovascular thrombectomy.

Official title: Efficacy and Safety of Anisodine Hydrobromide in Patients With Ischemic Stroke Undergoing Endovascular Treatment

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

204

Start Date

2026-08-31

Completion Date

2027-03-31

Last Updated

2026-09-02

Healthy Volunteers

No

Interventions

DRUG

Anisodine Hydrobromide

Anisodine hydrobromide, 2 mg per dose, diluted in 0.9% sodium chloride solution and administered by intravenous infusion twice daily for a total of 14 doses.

DRUG

Anisodine Hydrobromide Placebo

An equivalent volume of 0.9% sodium chloride solution, administered by intravenous infusion twice daily for a total of 14 doses.

Locations (11)

Anyang People's Hospital

Anyang, China

Xuanwu Hospital,Capital Medical University

Beijing, China

Anji County People's Hospital

Huzhou, China

Jiuquan People's Hospital

Jiuquan, China

Lishui Central Hospital

Lishui, China

Shangqiu First People's Hospitl

Shangqiu, China

Suzhou Municipal Hospital of Anhui Province

Suzhou, China

Taizhou Enze Medical Center (Group) Enze Hospital

Taizhou, China

The Affiliated Hospital of Xuzhou Medical University

Xuzhou, China

Zhangpu County Hospital

Zhangzhou, China

Zibo Central Hospital

Zibo, China